{(S)-2-[4-(2-Fluoro-ethyl)-piperidin-1-yl]-2-oxo-1-pyridin-2-ylmethyl-ethyl}-carbamic acid tert-butyl ester | 200268-01-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: {(S)-2-[4-(2-Fluoro-ethyl)-piperidin-1-yl]-2-oxo-1-pyridin-2-ylmethyl-ethyl}-carbamic acid tert-butyl ester
• 英文别名: tert-butyl N-[(2S)-1-[4-(2-fluoroethyl)piperidin-1-yl]-1-oxo-3-pyridin-2-ylpropan-2-yl]carbamate
• CAS: 200268-01-5
• 化学式: C₂₀H₃₀FN₃O₃
• 分子量: 379.475
• InChiKey: BUFZOXYNOVONHM-KRWDZBQOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  27
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  71.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  {(S)-2-[4-(2-Fluoro-ethyl)-piperidin-1-yl]-2-oxo-1-pyridin-2-ylmethyl-ethyl}-carbamic acid tert-butyl ester 在 盐酸 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成 4-Chloro-pyridine-3-sulfonic acid {(S)-2-[4-(2-fluoro-ethyl)-piperidin-1-yl]-2-oxo-1-pyridin-2-ylmethyl-ethyl}-amide
  参考文献：
  名称：

  The discovery of orally available thrombin inhibitors: Optimisation of the P1 pharmacophore

  摘要：

  Thrombin inhibitors have been designed with the replacement of the strongly basic guanidine P1 pharmocophore with a group that exploits the lipophilicty of the S1 pocket. The approach has lead to the discovery of potent thrombin inhibitors demonstrating good intra-duodenal absorption. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00138-9
• 作为产物：
  描述：

  Boc-3-(2-吡啶基)-L-丙氨酸 、 4-(2-fluoroethyl)piperidine hydrochloride 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 作用下， 以 二氯甲烷 为溶剂， 生成 {(S)-2-[4-(2-Fluoro-ethyl)-piperidin-1-yl]-2-oxo-1-pyridin-2-ylmethyl-ethyl}-carbamic acid tert-butyl ester
  参考文献：
  名称：

  The discovery of orally available thrombin inhibitors: Optimisation of the P1 pharmacophore

  摘要：

  Thrombin inhibitors have been designed with the replacement of the strongly basic guanidine P1 pharmocophore with a group that exploits the lipophilicty of the S1 pocket. The approach has lead to the discovery of potent thrombin inhibitors demonstrating good intra-duodenal absorption. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00138-9

文献信息

• The discovery of orally available thrombin inhibitors: Optimisation of the P1 pharmacophore
  作者：John Ambler、David Bentley、Lyndon Brown、Karen Dunnet、Dave Farr、Diana Janus、Darren Le Grand、Keith Menear、Mark Mercer、Mark Talbot、Morris Tweed、Bernard Wathey

  DOI：10.1016/s0960-894x(99)00138-9

  日期：1999.4

  Thrombin inhibitors have been designed with the replacement of the strongly basic guanidine P1 pharmocophore with a group that exploits the lipophilicty of the S1 pocket. The approach has lead to the discovery of potent thrombin inhibitors demonstrating good intra-duodenal absorption. (C) 1999 Elsevier Science Ltd. All rights reserved.